Results 191 to 200 of about 96,642 (272)
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip. [PDF]
DiMartino SJ+19 more
europepmc +1 more source
Rapid and Sustained Improvement of Lichen Planus Pemphigoides With the JAK1 Inhibitor Upadacitinib
ABSTRACT Lichen planus pemphigoides (LPP) is a rare autoimmune blistering disorder characteris ed by lichenoid plaques and blister formation. Current treatments are often ineffective, and there is a lack of standardised guidelines. The disease's pathogenesis involves both T‐cell‐mediated lichenoid dermatitis and autoantibody formation, presenting ...
Louise Gueissaz+2 more
wiley +1 more source
The Cognitive Footprint of Medication Use. [PDF]
Pinilla MS+4 more
europepmc +1 more source
ABSTRACT Background Atopic dermatitis (AD) is characterised by immune dysregulation and skin‐barrier dysfunction, which can predispose to microbial dysbiosis and skin infections. Fungi, particularly Malassezia, are common skin colonisers in AD patients and may exacerbate the condition.
Luis F. Andrade+8 more
wiley +1 more source
Associated diseases and their effects on disease course in patients with chronic non-bacterial osteomyelitis: retrospective experience from a single center. [PDF]
Öksüz Aydın B+4 more
europepmc +1 more source
Non-steroidal anti-inflammatory agents in patients with a renal transplant [PDF]
openaire +2 more sources
ABSTRACT Background Atopic dermatitis (AD) is a chronic, immune‐mediated, inflammatory skin disorder affecting a heterogeneous population. Most patients with mild‐to‐moderate AD are treated with topical medication. Objectives To gain an understanding of the management of mild‐to‐moderate AD with topical treatments by examining the practices of ...
Lawrence F. Eichenfield+14 more
wiley +1 more source
Presence of gluten and soy derived excipients in medicinal products and their implications on allergen safety and labeling. [PDF]
Figueiredo A+4 more
europepmc +1 more source
ABSTRACT Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus (1%–3% of CLE). There are two case reports to date in the literature of LEP potentially triggered by anti‐TNF‐α therapies. Clinically, it is characterised by tender, erythematous subcutaneous indurated nodules or plaques on fatty body areas.
Cristina Grechin+4 more
wiley +1 more source
Medication use and risk of reflux oesophagitis. [PDF]
Ueta R+15 more
europepmc +1 more source